Does the media refer more to ALKS or ABEO?

In the previous week, Abeona Therapeutics had 11 more articles in the media than Alkermes. MarketBeat recorded 15 mentions for Abeona Therapeutics and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.82 beat Abeona Therapeutics' score of 0.31 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abeona Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, ALKS or MEDP?

Medpace has higher revenue and earnings than Alkermes. Medpace is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alkermes $1.48B 4.74 $241.66M $0.38 109.71 Medpace $2.53B 6.72 $451.12M $17.06 35.69

Is ALKS or MEDP more profitable?

Medpace has a net margin of 17.67% compared to Alkermes' net margin of 3.96%. Medpace's return on equity of 110.15% beat Alkermes' return on equity. Company Net Margins Return on Equity Return on Assets Alkermes 3.96% 4.15% 2.19% Medpace 17.67% 110.15% 24.84%

Does the media favor ALKS or MEDP?

In the previous week, Medpace had 26 more articles in the media than Alkermes. MarketBeat recorded 30 mentions for Medpace and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.82 beat Medpace's score of 0.36 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 11 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, ALKS or OMCL?

Alkermes has higher revenue and earnings than Omnicell. Omnicell is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alkermes $1.48B 4.74 $241.66M $0.38 109.71 Omnicell $1.18B 1.30 $2.05M $0.84 40.26

Is ALKS or OMCL more profitable?

Alkermes has a net margin of 3.96% compared to Omnicell's net margin of 3.13%. Omnicell's return on equity of 5.66% beat Alkermes' return on equity. Company Net Margins Return on Equity Return on Assets Alkermes 3.96% 4.15% 2.19% Omnicell 3.13% 5.66% 3.57%

Does the media favor ALKS or OMCL?

In the previous week, Alkermes had 3 more articles in the media than Omnicell. MarketBeat recorded 4 mentions for Alkermes and 1 mentions for Omnicell. Alkermes' average media sentiment score of 0.82 beat Omnicell's score of 0.00 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omnicell 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ALKS or AMN?

In the previous week, Alkermes had 1 more articles in the media than AMN Healthcare Services. MarketBeat recorded 4 mentions for Alkermes and 3 mentions for AMN Healthcare Services. AMN Healthcare Services' average media sentiment score of 0.83 beat Alkermes' score of 0.82 indicating that AMN Healthcare Services is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AMN Healthcare Services 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, ROIV or ALKS?

Alkermes has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roivant Sciences $8.26M 3,119.79 -$299.77M -$0.53 N/A Alkermes $1.48B 4.74 $241.66M $0.38 109.71

Is ROIV or ALKS more profitable?

Alkermes has a net margin of 3.96% compared to Roivant Sciences' net margin of -3,534.96%. Alkermes' return on equity of 4.15% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Roivant Sciences -3,534.96% -22.94% -21.53% Alkermes 3.96% 4.15% 2.19%

Does the media refer more to ROIV or ALKS?

In the previous week, Alkermes had 1 more articles in the media than Roivant Sciences. MarketBeat recorded 4 mentions for Alkermes and 3 mentions for Roivant Sciences. Alkermes' average media sentiment score of 0.82 beat Roivant Sciences' score of -0.54 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative Alkermes 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Alkermes (ALKS) Competitors

$41.75 +1.21 (+2.98%)

Closing price 04:00 PM Eastern

Extended Trading

$41.64 -0.10 (-0.25%)

As of 06:07 PM Eastern

Compare

ALKS vs. ABEO, MEDP, OMCL, AMN, and ROIV

Should you buy Alkermes stock or one of its competitors? Alkermes's main competitors and comparable companies include Abeona Therapeutics (ABEO), Medpace (MEDP), Omnicell (OMCL), AMN Healthcare Services (AMN), and Roivant Sciences (ROIV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Alkermes compare to Abeona Therapeutics?

Alkermes (NASDAQ:ALKS) and Abeona Therapeutics (NASDAQ:ABEO) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

Alkermes has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.74	$241.66M	$0.38	109.71
Abeona Therapeutics	$5.82M	49.86	$71.18M	-$1.09	N/A

Alkermes presently has a consensus price target of $54.47, indicating a potential upside of 30.66%. Abeona Therapeutics has a consensus price target of $21.00, indicating a potential upside of 313.79%. Given Abeona Therapeutics' higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Alkermes has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

In the previous week, Abeona Therapeutics had 11 more articles in the media than Alkermes. MarketBeat recorded 15 mentions for Abeona Therapeutics and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.82 beat Abeona Therapeutics' score of 0.31 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abeona Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alkermes has a net margin of 3.96% compared to Abeona Therapeutics' net margin of 0.00%. Alkermes' return on equity of 4.15% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Abeona Therapeutics	N/A	-41.69%	-30.36%

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Comparatively, 7.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Alkermes beats Abeona Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Alkermes compare to Medpace?

Alkermes (NASDAQ:ALKS) and Medpace (NASDAQ:MEDP) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Alkermes presently has a consensus price target of $54.47, suggesting a potential upside of 30.66%. Medpace has a consensus price target of $602.27, suggesting a potential downside of 1.09%. Given Alkermes' stronger consensus rating and higher probable upside, equities analysts plainly believe Alkermes is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23

95.2% of Alkermes shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 4.6% of Alkermes shares are held by insiders. Comparatively, 20.5% of Medpace shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Medpace had 26 more articles in the media than Alkermes. MarketBeat recorded 30 mentions for Medpace and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.82 beat Medpace's score of 0.36 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	11 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alkermes has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Medpace has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

Medpace has higher revenue and earnings than Alkermes. Medpace is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.74	$241.66M	$0.38	109.71
Medpace	$2.53B	6.72	$451.12M	$17.06	35.69

Medpace has a net margin of 17.67% compared to Alkermes' net margin of 3.96%. Medpace's return on equity of 110.15% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Medpace	17.67%	110.15%	24.84%

Summary

Medpace beats Alkermes on 10 of the 17 factors compared between the two stocks.

How does Alkermes compare to Omnicell?

Alkermes (NASDAQ:ALKS) and Omnicell (NASDAQ:OMCL) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

95.2% of Alkermes shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 4.6% of Alkermes shares are held by insiders. Comparatively, 2.9% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Alkermes presently has a consensus price target of $54.47, suggesting a potential upside of 30.66%. Omnicell has a consensus price target of $57.86, suggesting a potential upside of 71.07%. Given Omnicell's stronger consensus rating and higher probable upside, analysts plainly believe Omnicell is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Alkermes has higher revenue and earnings than Omnicell. Omnicell is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.74	$241.66M	$0.38	109.71
Omnicell	$1.18B	1.30	$2.05M	$0.84	40.26

In the previous week, Alkermes had 3 more articles in the media than Omnicell. MarketBeat recorded 4 mentions for Alkermes and 1 mentions for Omnicell. Alkermes' average media sentiment score of 0.82 beat Omnicell's score of 0.00 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omnicell	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alkermes has a net margin of 3.96% compared to Omnicell's net margin of 3.13%. Omnicell's return on equity of 5.66% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Omnicell	3.13%	5.66%	3.57%

Alkermes has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Omnicell has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

Summary

Alkermes beats Omnicell on 10 of the 17 factors compared between the two stocks.

How does Alkermes compare to AMN Healthcare Services?

Alkermes (NASDAQ:ALKS) and AMN Healthcare Services (NYSE:AMN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Alkermes currently has a consensus target price of $54.47, indicating a potential upside of 30.66%. AMN Healthcare Services has a consensus target price of $36.00, indicating a potential downside of 2.01%. Given Alkermes' stronger consensus rating and higher possible upside, equities analysts clearly believe Alkermes is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74
AMN Healthcare Services	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Alkermes has higher earnings, but lower revenue than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.74	$241.66M	$0.38	109.71
AMN Healthcare Services	$2.73B	0.52	-$95.70M	$2.68	13.71

Alkermes has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

In the previous week, Alkermes had 1 more articles in the media than AMN Healthcare Services. MarketBeat recorded 4 mentions for Alkermes and 3 mentions for AMN Healthcare Services. AMN Healthcare Services' average media sentiment score of 0.83 beat Alkermes' score of 0.82 indicating that AMN Healthcare Services is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AMN Healthcare Services	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Comparatively, 1.1% of AMN Healthcare Services shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Alkermes has a net margin of 3.96% compared to AMN Healthcare Services' net margin of 3.06%. AMN Healthcare Services' return on equity of 19.92% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
AMN Healthcare Services	3.06%	19.92%	5.93%

Summary

Alkermes beats AMN Healthcare Services on 10 of the 17 factors compared between the two stocks.

How does Alkermes compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Roivant Sciences has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

In the previous week, Alkermes had 1 more articles in the media than Roivant Sciences. MarketBeat recorded 4 mentions for Alkermes and 3 mentions for Roivant Sciences. Alkermes' average media sentiment score of 0.82 beat Roivant Sciences' score of -0.54 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative
Alkermes	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alkermes has a net margin of 3.96% compared to Roivant Sciences' net margin of -3,534.96%. Alkermes' return on equity of 4.15% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Alkermes	3.96%	4.15%	2.19%

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by insiders. Comparatively, 4.6% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Alkermes has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,119.79	-$299.77M	-$0.53	N/A
Alkermes	$1.48B	4.74	$241.66M	$0.38	109.71

Roivant Sciences currently has a consensus target price of $45.64, indicating a potential upside of 27.92%. Alkermes has a consensus target price of $54.47, indicating a potential upside of 30.66%. Given Alkermes' higher possible upside, analysts plainly believe Alkermes is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Alkermes	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74

Summary

Alkermes beats Roivant Sciences on 13 of the 17 factors compared between the two stocks.

Get Alkermes News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALKS vs. The Competition

Export

Metric	Alkermes	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.00B	$3.84B	$7.10B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	109.87	12.99	274.61	26.05
Price / Sales	4.75	1,288.54	601.02	89.39
Price / Cash	24.20	121.76	77.38	51.25
Price / Book	3.79	16.63	10.92	6.31
Net Income	$241.66M	-$22.67M	$3.50B	$361.43M
7 Day Performance	2.20%	-3.06%	-2.11%	-1.67%
1 Month Performance	-12.51%	-10.76%	-6.34%	-3.94%
1 Year Performance	33.56%	21.10%	8.81%	2.77%

Alkermes Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALKS Alkermes	3.0833 of 5 stars	$41.75 +3.0%	$54.47 +30.5%	+32.3%	$7.00B	$1.48B	109.87	2,050
ABEO Abeona Therapeutics	2.9849 of 5 stars	$5.29 -2.0%	$21.00 +297.0%	-5.1%	$308.79M	$5.82M	N/A	226	Insider Trade
MEDP Medpace	2.3641 of 5 stars	$615.94 -0.5%	$595.20 -3.4%	+10.0%	$17.27B	$2.53B	36.10	6,200	Trending News Analyst Upgrade Insider Trade
OMCL Omnicell	3.5017 of 5 stars	$33.87 +0.6%	$57.86 +70.8%	+11.6%	$1.53B	$1.18B	40.32	3,580
AMN AMN Healthcare Services	1.4411 of 5 stars	$34.20 -1.0%	$36.00 +5.3%	+80.0%	$1.34B	$2.73B	12.76	2,664

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALKS) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alkermes (ALKS) Competitors

ALKS vs. ABEO, MEDP, OMCL, AMN, and ROIV

How does Alkermes compare to Abeona Therapeutics?

Summary

How does Alkermes compare to Medpace?

Summary

How does Alkermes compare to Omnicell?

Summary

How does Alkermes compare to AMN Healthcare Services?

Summary

How does Alkermes compare to Roivant Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALKS vs. The Competition

Alkermes Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alkermes (ALKS) Competitors

ALKS vs. ABEO, MEDP, OMCL, AMN, and ROIV

How does Alkermes compare to Abeona Therapeutics?

Which has higher earnings and valuation, ALKS or ABEO?

Do analysts recommend ALKS or ABEO?

Which has more volatility & risk, ALKS or ABEO?

Does the media refer more to ALKS or ABEO?

Is ALKS or ABEO more profitable?

Do institutionals and insiders believe in ALKS or ABEO?

Summary

How does Alkermes compare to Medpace?

Do analysts recommend ALKS or MEDP?

Do insiders and institutionals hold more shares of ALKS or MEDP?

Does the media favor ALKS or MEDP?

Which has more risk and volatility, ALKS or MEDP?

Which has stronger valuation & earnings, ALKS or MEDP?

Is ALKS or MEDP more profitable?

Summary

How does Alkermes compare to Omnicell?

Do institutionals and insiders hold more shares of ALKS or OMCL?

Do analysts recommend ALKS or OMCL?

Which has stronger valuation and earnings, ALKS or OMCL?

Does the media favor ALKS or OMCL?

Is ALKS or OMCL more profitable?

Which has more volatility & risk, ALKS or OMCL?

Summary

How does Alkermes compare to AMN Healthcare Services?

Do analysts recommend ALKS or AMN?

Which has higher earnings & valuation, ALKS or AMN?

Which has more volatility & risk, ALKS or AMN?

Does the media refer more to ALKS or AMN?

Do institutionals and insiders believe in ALKS or AMN?

Is ALKS or AMN more profitable?

Summary

How does Alkermes compare to Roivant Sciences?

Which has more risk & volatility, ROIV or ALKS?

Does the media refer more to ROIV or ALKS?

Is ROIV or ALKS more profitable?

Do insiders & institutionals hold more shares of ROIV or ALKS?

Which has better valuation & earnings, ROIV or ALKS?

Do analysts recommend ROIV or ALKS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALKS vs. The Competition

Alkermes Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools